Quantcast

Latest human disease Stories

2010-08-02 05:30:00

THE WOODLANDS, Texas, Aug. 2 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug...

2010-06-24 04:23:50

Discovery introduces a new group of genetic entities, dubbed 'competitive endogenous RNAs' The central dogma of molecular biology, as proposed in 1970 by Francis Crick and James Watson, holds that genetic information is transferred from DNA to functional proteins by way of messenger RNA (mRNA). This suggests that mRNA has but a single role, that being to encode for proteins. Now, a cancer genetics team at Beth Israel Deaconess Medical Center (BIDMC) suggests there is much more to RNA than...

2010-06-15 18:00:00

THE WOODLANDS, Texas, June 15 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will be presenting clinical data from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010: The 92nd Annual Meeting and Expo, June 19 - 22, 2010 in San Diego, California and the 70th Scientific Sessions of the American Diabetes...

2010-05-10 05:00:00

THE WOODLANDS, Texas, May 10 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010. "Achieving the remarkable results from our Phase 2a trial of LX4211 in patients with type 2 diabetes was the defining event of the first quarter," said Dr. Arthur...

2010-02-23 05:30:00

THE WOODLANDS, Texas, Feb. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009. "We have now established proof-of-concept for two of our four clinical programs, with positive results in Phase 2 clinical trials for both LX1031 in...

2010-01-26 12:29:37

Scientists at Duke University Medical Center say they are now convinced that rare genetic variants "“ as opposed to more common ones "“ lie at the heart of the genetic component of most common diseases. The finding appearing in PLoS Biology, stems from a series of simulation studies, and challenges common interpretations of a multitude of genome-wide association studies (GWAS) that have identified thousands of single-DNA letter changes associated with greater risk of common...

2010-01-20 05:30:00

THE WOODLANDS, Texas, Jan. 20 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of...

2009-08-19 06:23:56

The ability to specifically target and modify genes in the mouse allows researchers to use this small rodent to study how certain genes contribute to human disease. A common method used to make genetic changes in mice and cells is called site-specific recombination, where two DNA strands are exchanged. The two strands may contain very different sequences, but are designated at their ends by specific target sequences that are not commonly found elsewhere in the genome. A protein, called a...

2009-08-04 05:30:00

THE WOODLANDS, Texas, Aug. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX2931 in patients with rheumatoid arthritis. LX2931 is an orally-delivered, small molecule drug candidate that has recently completed Phase 1 testing in normal volunteers. Lexicon also successfully completed a...

2009-07-28 05:30:00

THE WOODLANDS, Texas, July 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and six months ended June 30, 2009. "Our clinical development programs continue to progress, including the recent initiation of a Phase 2 study of LX1032 in patients with carcinoid...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related